Illumina, Inc.

Sector: Companies & groupsHQ: UNITED STATES

EU Lobbying Profiles

Illumina, Inc.

Register: EU_TRANSPARENCY_REGISTER

Declared Spend (Max)

€999,999

Regulatory Meetings

Discussion on implementation of Regulation (EU) n° 2025/179

Met with Koen Van Dyck (EU)

To give an update of recent development in the company and sector

Met with Michele Piergiovanni (EU)

Exchange on Life Sciences Strategy and next Framework 
 Programme

Met with Andreas Schwarz (EU)

Exchange on Life Sciences Strategy and next Framework 
 Programme

Met with Alexandra Hild (EU)

Exchange of views on how to leverage of genomics data to 
 accelerate breakthroughs in precision medicine and to support the 
 implementation of Horizon Europe

Met with Carmen Laplaza Santos (EU)

Genomic research in Europe

Met with Vilija Sysaite (EU)

Cancer Screening tests, Illumina-GRAIL Merger

Met with Katherine Power (EU)

The public health benefits and competition issues arising out of the merger between Illumina and GRAIL

Met with Joanna Stawowy (EU)

Presentation of an early screening test by a cancer screening start-up. Its impact on health, early detection of cancer and especially on most vulnerable groups was discussed in the context of equality policy and the EU Beating Cancer strategy

Met with Eva Gerhards (EU)

Presentation of the merger case Illumina and Grail

Met with Carole Mancel-Blanchard (EU)

Government Procurement

Denmark – Laboratory, optical and precision equipments (excl. glasses) – Large-Scale Array System → Illumina Denmark ApS — Contract awarded to Illumina Denmark ApS by Region Hovedstaden

Value: €857,909

Executive Insider Trades

No executive insider trades reported.